Biography

    Dr. Brogly's research addresses the reproductive health and perinatal outcomes of marginalized populations including substance users, HIV infected women and children, and young minority women.  She is the Principal Investigator of several foundation and BUMC funded studies.  Dr. Brogly is currently collaborating with clinical providers of BMC’s Project RESPECT clinic to study the effect of prenatal exposure to opioid agonist therapies on neonatal abstinence syndrome (NAS), and with the Department of Pediatrics to study sleep disruptions and NAS pathophysiology.  Prior to joining BUSPH Dr. Brogly held an appointment from 2002-2009 in the Center for Biostatistics in AIDS Research at Harvard University.

Courses Taught in Other Semesters
Publications
    1. Perkins RB, Brogly SB, Adams WG, Freund KM. Correlates of human papillomavirus vaccination rates in low-income, minority adolescents: a multicenter study. J Womens Health (Larchmt). 2012 Aug; 21(8):813-20.
      View in: PubMed
     
    2. Knapp KM, Brogly SB, Muenz DG, Spiegel HM, Conway DH, Scott GB, Talbot JT, Shapiro DE, Read JS. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J. 2012 Feb; 31(2):164-70.
      View in: PubMed
     
    3. Brogly SB, Dimauro S, Van Dyke RB, Williams PL, Naini A, Libutti DE, Choi J, Chung M, Gerschenson M. Short Communication: Transplacental Nucleoside Analogue Exposure and Mitochondrial Parameters in HIV-Uninfected Children. AIDS Res Hum Retroviruses. 2011 Jul; 27(7):777-83.
      View in: PubMed
     
    4. Tassiopoulos K, Read JS, Brogly S, Rich K, Lester B, Spector SA, Yogev R, Seage GR. Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis. AIDS Behav. 2010 Dec; 14(6):1269-78.
      View in: PubMed
     
    5. Brogly SB, Abzug MJ, Watts DH, Cunningham CK, Williams PL, Oleske J, Conway D, Sperling RS, Spiegel H, Van Dyke RB. Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J. 2010 Aug; 29(8):721-7.
      View in: PubMed
     
    6. Livingston EG, Huo Y, Patel K, Brogly SB, Tuomala R, Scott GB, Bardeguez A, Stek A, Read JS. Mode of delivery and infant respiratory morbidity among infants born to HIV-1-infected women. Obstet Gynecol. 2010 Aug; 116(2 Pt 1):335-43.
      View in: PubMed
     
    7. Crain MJ, Chernoff MC, Oleske JM, Brogly SB, Malee KM, Borum PR, Meyer WA, Mitchell WG, Moye JH, Ford-Chatterton HM, Van Dyke RB, Seage Iii GR. Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV. J Infect Dis. 2010 Jul 15; 202(2):291-301.
      View in: PubMed
     
    8. Patel K, Shapiro DE, Brogly SB, Livingston EG, Stek AM, Bardeguez AD, Tuomala RE. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis. 2010 Apr 1; 201(7):1035-44.
      View in: PubMed
     
    9. Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. Pediatrics. 2010 Feb; 125(2):e250-60.
      View in: PubMed
     
    10. Ouyang DW, Brogly SB, Lu M, Shapiro DE, Hershow RC, French AL, Leighty RM, Thompson B, Tuomala RE. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS. 2010 Jan 2; 24(1):109-14.
      View in: PubMed
     
    11. Brogly SB, Foca M, Deville JG, Mirochnick M, Scott GB, Mofenson LM, Read JS, Viani RM, Burchett SK, Cooper ER, Browning R, Shapiro DE. Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants. J Acquir Immune Defic Syndr. 2010 Jan 1; 53(1):154-7.
      View in: PubMed
     
    12. Ouyang DW, Shapiro DE, Lu M, Brogly SB, French AL, Leighty RM, Thompson B, Tuomala RE, Hershow RC. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. AIDS. 2009 Nov 27; 23(18):2425-30.
      View in: PubMed
     
    13. Read JS, Brogly S, Basar M, Scott G. Human immunodeficiency virus diagnostic testing of infants at clinical sites in North America: 2002-2006. Pediatr Infect Dis J. 2009 Jul; 28(7):614-8.
      View in: PubMed
     
    14. Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, Abzug MJ, Brady M, Jean-Philippe P, Hughes MD, Seage GR. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS. 2007 May 11; 21(8):929-38.
      View in: PubMed
     
    15. Brogly SB, Watts DH, Ylitalo N, Franco EL, Seage GR, Oleske J, Eagle M, Van Dyke R. Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health. 2007 Jun; 97(6):1047-52.
      View in: PubMed
     
    16. Brogly S, Read JS, Shapiro D, Stek A, Tuomala R. Participation of HIV-infected pregnant women in research in the United States. AIDS Res Hum Retroviruses. 2007 Jan; 23(1):51-3.
      View in: PubMed
     
    17. Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Pediatr Adolesc Med. 2006 Aug; 160(8):778-87.
      View in: PubMed
     
    18. Brogly S, Williams P, Seage GR, Van Dyke R. In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and 219C cohorts. J Acquir Immune Defic Syndr. 2006 Apr 1; 41(4):535-6.
      View in: PubMed
     
    19. Brogly S, Williams P, Seage GR, Oleske JM, Van Dyke R, McIntosh K. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA. 2005 May 11; 293(18):2213-20.
      View in: PubMed
     
    20. Kest H, Brogly S, McSherry G, Dashefsky B, Oleske J, Seage GR. Malignancy in perinatally human immunodeficiency virus-infected children in the United States. Pediatr Infect Dis J. 2005 Mar; 24(3):237-42.
      View in: PubMed
     
    21. Bruneau J, Brogly SB, Tyndall MW, Lamothe F, Franco EL. Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization. Addiction. 2004 Jun; 99(6):727-37.
      View in: PubMed
     
    22. Brogly S, Mercier C, Bruneau J, Palepu A, Franco E. Towards more effective public health programming for injection drug users: development and evaluation of the injection drug user quality of life scale. Subst Use Misuse. 2003 Jun; 38(7):965-92.
      View in: PubMed
     
    23. Tyndall MW, Bruneau J, Brogly S, Spittal P, O'Shaughnessy MV, Schechter MT. Satellite needle distribution among injection drug users: policy and practice in two canadian cities. J Acquir Immune Defic Syndr. 2002 Sep 1; 31(1):98-105.
      View in: PubMed
     
    24. Kulaga S, Hagel B, Brogly S, Momoli F. Epidemiology research. Lancet. 2002 Jul 20; 360(9328):259-60; author reply 260.
      View in: PubMed
     
    25. Brogly SB, Bruneau J, Lamothe F, Vincelette J, Franco EL. HIV-positive notification and behavior changes in Montreal injection drug users. AIDS Educ Prev. 2002 Feb; 14(1):17-28.
      View in: PubMed
     
    26. Brogly SB, Bruneau J, Vincelette J, Lamothe F, Franco EL. Risk behaviour change and HIV infection among injection drug users in Montreal. AIDS. 2000 Nov 10; 14(16):2575-82.
      View in: PubMed